What is AVS?
Founded in 2017 by Dr. Hitinder Gurm and Dr. Robert Chisena, AVS is a medical technology company dedicated to redefining interventional therapy for patients suffering from severely calcified lesions. The company's flagship innovation, the Pulse IVL system, represents a significant advancement in intravascular lithotripsy. By leveraging sophisticated engineering, AVS provides physicians with a safer and more effective tool to address complex arterial conditions that were previously difficult to treat. The company operates at the intersection of clinical excellence and medical engineering, aiming to transform standard-of-care protocols in cardiovascular medicine.
How much funding has AVS raised?
AVS has raised a total of $64.8M across 3 funding rounds:
Series B
$20M
Series B
$8.8M
Series B
$36M
Series B (2023): $20M with participation from BioStar Capital
Series B (2023): $8.8M led by BioStar Capital
Series B (2025): $36M supported by CUE Growth Partners and BioStar Capital
Key Investors in AVS
CUE Growth Partners
Cue Growth Partners is a Growth Equity firm based in New York that specializes in providing flexible capital at the intersection of venture capital and private equity, focusing on transformational healthcare technology.
BioStar Capital
BioStar Capital invests in and nurtures transformative medical technologies, leveraging a team of renowned healthcare clinicians, medical thought leaders, and financial professionals to drive life-changing outcomes.
What's next for AVS?
With this major enterprise-level funding, AVS is poised to transition into a critical phase of commercial scaling and clinical validation. The strategic roadmap likely includes the expansion of human clinical trials and the strengthening of regulatory pathways to ensure the Pulse IVL system achieves widespread adoption. As the company continues to refine its technology, the focus will remain on delivering superior patient outcomes while navigating the complexities of the global medical device market. Investors are expected to monitor the company's progress in securing further clinical data and establishing key partnerships with major health systems to solidify its market position.
See full AVS company page
